生物标志物的异常表达和巴雷特食道失生症中新生变化的风险预测

生物标志物的异常表达和巴雷特食道失生症中新生变化的风险预测

相关实验视频

Updated: Jun 21, 2025

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

06:55

Diagnosis of Neoplasia in Barrett’s Esophagus using Vital-dye Enhanced Fluorescence Imaging

Published on: May 11, 2014

12.0K

Young Choi¹, Andrew Bedford², Simcha Pollack³

¹Department of Pathology, Yale School of Medicine, 434 Pine Grove Lane, Hartsdale, NY 10530, USA.

Cancers

|July 13, 2024

概括

使用粘素2 (MUC2) 和三叶草因子3 (TFF3) 的生物标志物测试有助于诊断巴雷特食道 (BE). 异常的蛋白质表达也有助于降级发育不良并预测BE患者的进展风险.

科学领域:

胃肠病学胃肠病学
在瘤学瘤学.
分子病理学分子病理学

背景情况:

巴雷特食道 (BE) 是食道腺癌 (EAC) 的癌前病症.
精确的诊断和BE中的失形分级对于患者管理至关重要,但由于常规组织学中的观察者间变异性而面临挑战.
生物标志物测试对于提高BE的诊断准确性和风险分层至关重要.

研究的目的:

为了确定特定的生物标志物用于准确的BE诊断.
寻找可预测BE与发育不良进展风险的生物标志物.
为了减少BE诊断和分级的观察者间变异性.

主要方法:

免疫组织化学被用来分析粘素2 (MUC2),三叶草因子3 (TFF3),p53,p16,环素D1,Ki-67,β-catenin和微染色体维护 (MCM2) 在活检中.
光现场杂交 (FISH) 在刷样本上进行,以检测染色体变化.
研究包括对活检的回顾性分析和对新鲜样本的前性分析.

主要成果:

MUC2和TFF3被确定为BE的特定诊断标志物.
对p53,Ki-67,p16,β-catenin,cyclin D1和MCM2的异常表达显著与低度形 (LGD),高度形 (HGD) 和EAC相关.
在BE中异常的p53和p16表达与无限期发育不良 (IND) 预测的进展风险.

结论:

生物标志物评估是组织学的一个有价值的辅助工具,用于准确地诊断BE和分类发育不良.
这些生物标志物可以帮助减少观察者间的变异性,特别是对于LGD.
生物标志物分析改善了在BE中预测瘤进展的可能性.

关键词:

在BEDDysplasia中.巴雷特的食道.生物标志物生物标志物诊断助理诊断助理诊断助理诊断助理消化道腺癌 (adenocarcinoma) 的发生风险预测风险预测

更多相关视频

Development of Compendium for Esophageal Squamous Cell Carcinoma

03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

399

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.0K

相关概念视频

01:21

Barrett Esophagus-I: Introduction

81

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...

81

Barrett Esophagus-II: Clinical Manifestations and Management

01:21

Barrett Esophagus-II: Clinical Manifestations and Management

135

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...

135

02:07

Tumor Progression

6.3K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...